Skip to main content

Abstract

Atrial fibrillation (AF) is the most frequent sustained arrhythmia in the elderly. AF is often associated with (and aggravates the clinical course of) several age-related disorders, such as chronic heart failure, non-ST-elevation myocardial infarction, cerebrovascular disease, chronic obstructive pulmonary disease, pneumonia, and urinary infections. Older patients can develop the most severe complications of AF, such as stroke and dementia. Despite existing evidence, oral anticoagulation is still underused in the elderly. A rate-control strategy is frequently adopted. In conclusion, AF in elderly patients is common and often represents a marker of multiple comorbidities and frailty. Management should aim at reducing symptoms and improving health-related quality of life and survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.

    Article  PubMed  Google Scholar 

  2. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746–51.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–47.

    Article  PubMed  Google Scholar 

  4. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.

    Article  PubMed  Google Scholar 

  5. Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ. 2009;339:b4904. doi:10.1136/bmj.b4904.:b4904.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Pan NH, Tsao HM, Chang NC, Chen YJ, Chen SA. Aging dilates atrium and pulmonary veins: implications for the genesis of atrial fibrillation. Chest. 2008;133:190–6.

    Article  PubMed  Google Scholar 

  7. McManus DD, Xanthakis V, Sullivan LM, et al. Longitudinal tracking of left atrial diameter over the adult life course: clinical correlates in the community. Circulation. 2010;121:667–74.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gramley F, Lorenzen J, Knackstedt C, et al. Age-related atrial fibrosis. Age (Dordr). 2009;31:27–38.

    Article  CAS  Google Scholar 

  9. Burkauskiene A, Mackiewicz Z, Virtanen I, Konttinen YT. Age-related changes in myocardial nerve and collagen networks of the auricle of the right atrium. Acta Cardiol. 2006;61:513–8.

    Article  PubMed  Google Scholar 

  10. Asirvatham SJ, Gard JJ. Wrinkles in the atrium: age, atrial fibrillation, or something else. J Am Coll Cardiol. 2011;58:2233–5.

    Article  PubMed  Google Scholar 

  11. Bejot Y, Ben Salem D, Osseby GV, et al. Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology. 2009;72:346–53.

    Article  CAS  PubMed  Google Scholar 

  12. Yiin GS, Howard DP, Paul NL, et al. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation. 2014;130:1236–44.

    Article  CAS  PubMed  Google Scholar 

  13. Leyden JM, Kleinig TJ, Newbury J, et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke. 2013;44:1226–31.

    Article  PubMed  Google Scholar 

  14. Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology. 2013;80:1546–50.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Marfella R, Sasso FC, Siniscalchi M, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013;62:525–30.

    Article  PubMed  Google Scholar 

  16. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32:392–8.

    Article  CAS  PubMed  Google Scholar 

  17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.

    Article  PubMed  Google Scholar 

  18. Bekwelem W, Connolly SJ, Halperin JL, et al. Extracranial systemic embolic events in patients with nonvalvular atrial fibrillation: incidence, risk factors, and outcomes. Circulation. 2015;132:796–803.

    Article  PubMed  Google Scholar 

  19. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:2946–53.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119:1363–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.

    Article  CAS  PubMed  Google Scholar 

  22. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127:224–32.

    Article  CAS  PubMed  Google Scholar 

  23. Boriani G, Savelieva I, Dan GA, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015;17:1169–96.

    Article  PubMed  Google Scholar 

  24. Jover E, Marin F, Roldan V, Montoro-Garcia S, Valdes M, Lip GY. Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. Ann Med. 2013;45:274–90.

    Article  CAS  PubMed  Google Scholar 

  25. Anandasundaram B, Lane DA, Apostolakis S, Lip GY. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. J Thromb Haemost. 2013;11:975–87.

    Article  CAS  PubMed  Google Scholar 

  26. Mitchell GF, Vasan RS, Keyes MJ, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297:709–15.

    Article  CAS  PubMed  Google Scholar 

  27. Violi F, Davi G, Hiatt W, et al. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol. 2013;62:2255–6.

    Article  PubMed  Google Scholar 

  28. Violi F, Davi G, Proietti M, et al. Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. Thromb Haemost. 2016;115:856–63.

    Article  PubMed  Google Scholar 

  29. Fumagalli S, Gabbai D, Nreu B, et al. Age, left atrial dimension and arterial stiffness after external cardioversion of atrial fibrillation. A vascular component in arrhythmia maintenance? Results from a preliminary study. Aging Clin Exp Res. 2014;26:327–30.

    Article  PubMed  Google Scholar 

  30. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.

    Article  PubMed  Google Scholar 

  31. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 1997;28:316–21.

    Article  CAS  PubMed  Google Scholar 

  32. Miyasaka Y, Barnes ME, Petersen RC, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J. 2007;28:1962–7.

    Article  PubMed  Google Scholar 

  33. Thacker EL, McKnight B, Psaty BM, et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology. 2013;81:119–25.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Dublin S, Anderson ML, Haneuse SJ, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc. 2011;59:1369–75.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76:914–22.

    Article  CAS  PubMed  Google Scholar 

  36. Udompanich S, Lip GY, Apostolakis S, Lane DA. Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. QJM. 2013;106:795–802.

    Article  CAS  PubMed  Google Scholar 

  37. Swardfager W, Black SE. Coronary artery calcification: a canary in the cognitive coalmine. J Am Coll Cardiol. 2016;67:1023–6.

    Article  PubMed  Google Scholar 

  38. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res. 2007;32:1749–56.

    Article  CAS  PubMed  Google Scholar 

  39. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  40. Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161:241–6.

    Article  PubMed  Google Scholar 

  41. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.

    Article  CAS  PubMed  Google Scholar 

  42. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297–305.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged >/=75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015;46:143–50.

    Article  PubMed  Google Scholar 

  44. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298–307.

    Article  CAS  PubMed  Google Scholar 

  45. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124:824–9.

    Article  CAS  PubMed  Google Scholar 

  46. Fumagalli S, Nieuwlaat R, Tarantini F, et al. Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation. Aging Clin Exp Res. 2012;24:517–23.

    PubMed  Google Scholar 

  47. Fumagalli S, Said S, Laroche C, et al. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: The EORP-AF general pilot registry (EUR Observational Research Programme-Atrial Fibrillation). JACC Clin Electrophysiol. 2015;1:326–34.

    Article  Google Scholar 

  48. Flaker GC, Pogue J, Yusuf S, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:277–83.

    Article  PubMed  Google Scholar 

  49. Jacobs V, Woller SC, Stevens S, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm. 2014;11:2206–13.

    Article  PubMed  Google Scholar 

  50. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  CAS  PubMed  Google Scholar 

  51. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.

    Article  CAS  PubMed  Google Scholar 

  52. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  CAS  PubMed  Google Scholar 

  53. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  CAS  PubMed  Google Scholar 

  54. Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2013;126:289–96.

    Article  CAS  PubMed  Google Scholar 

  55. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  CAS  PubMed  Google Scholar 

  56. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453–60.

    Article  CAS  PubMed  Google Scholar 

  58. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014;62:857–64.

    Article  PubMed  Google Scholar 

  59. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.

    Article  CAS  PubMed  Google Scholar 

  60. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.

    Article  PubMed  Google Scholar 

  61. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.

    Article  PubMed  Google Scholar 

  62. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–94.

    Article  CAS  PubMed  Google Scholar 

  63. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–30.

    Article  CAS  PubMed  Google Scholar 

  64. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–64.

    Article  CAS  PubMed  Google Scholar 

  65. Fumagalli S, Cardini F, Roberts AT, et al. Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary report. Aging Clin Exp Res. 2015;27:99–102.

    Article  PubMed  Google Scholar 

  66. Shariff N, Desai RV, Patel K, et al. Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation. Am J Med. 2013;126:887–93.

    Article  PubMed  Google Scholar 

  67. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509–13.

    Article  PubMed  Google Scholar 

  68. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913–20.

    Article  CAS  PubMed  Google Scholar 

  69. Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64:1541–50.

    Article  CAS  PubMed  Google Scholar 

  70. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719–28.

    Article  CAS  PubMed  Google Scholar 

  71. Chao TF, Liu CJ, Tuan TC, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015;132:1604–12.

    Article  CAS  PubMed  Google Scholar 

  72. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235–43.

    Article  CAS  PubMed  Google Scholar 

  73. Shah M, Avgil TM, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients >/=65 years of age with versus without heart failure. Am J Cardiol. 2014;114:401–6.

    Article  CAS  PubMed  Google Scholar 

  74. Mulder BA, Van Veldhuisen DJ, Crijns HJ, et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014;11:1543–50.

    Article  PubMed  Google Scholar 

  75. Nademanee K, Amnueypol M, Lee F, et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm. 2015;12:44–51.

    Article  PubMed  Google Scholar 

  76. Fiala M, Wichterle D, Bulkova V, et al. A prospective evaluation of haemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long-standing persistent atrial fibrillation. Europace. 2014;16:15–25.

    Article  PubMed  Google Scholar 

  77. Fumagalli S, Tarantini F, Guarducci L, et al. Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA Study. Aging Clin Exp Res. 2010;22:129–33.

    Article  CAS  PubMed  Google Scholar 

  78. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–56.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stefano Fumagalli MD, PhD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fumagalli, S., Gabbai, D., Padeletti, L., Crijns, H.J., Lip, G.Y.H. (2017). Atrial Fibrillation in the Elderly. In: Ungar, A., Marchionni, N. (eds) Cardiac Management in the Frail Elderly Patient and the Oldest Old. Springer, Cham. https://doi.org/10.1007/978-3-319-43468-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43468-1_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43466-7

  • Online ISBN: 978-3-319-43468-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics